Skip to Content

Deferoxamine Injection

Last Updated: May 4, 2020
Status: Current

Products Affected - Description
    • Deferoxamine injection, Almaject, 2 gram, vial, 1 count, NDC 47781-0624-07
    • Deferoxamine injection, Fresenius Kabi, 2 gram, vial, 1 count, NDC 63323-0599-30
    • Deferoxamine injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0597-10
Reason for the Shortage
    • Fresenius Kabi had deferoxamine on shortage due to increased demand.
    • Pfizer had deferoxamine on shortage due to manufacturing delays.
    • Novartis has Desferal available.
    • Almaject did not provide a reason for the shortage. Almaject discontinued the 500 mg vials in late-2019.
    • Apo-Pharma launched deferoxamine injection in mid-2018.
Available Products
    • Desferal injection, Novartis, 500 mg, vial, 4 count, NDC 00078-0467-91
    • Deferoxamine injection, Apo-Pharma, 2 gram, vial, 4 count, NDC 52609-4504-06
    • Deferoxamine injection, Apo-Pharma, 500 mg, vial, 4 count, NDC 52609-4505-06
    • Deferoxamine injection, Pfizer, 2 gram, vial, 4 count, NDC 00409-2337-25
    • Deferoxamine injection, Pfizer, 500 mg, vial, 4 count, NDC 00409-2336-10

Estimated Resupply Dates

    • Almaject has short-dated deferoxamine 2 gram vials available with an expiration date of June 2020.
    • Fresenius Kabi has deferoxamine 500 mg and 2 gram vials on back order and the company estimates a release date of mid-June 2020 for the 500 mg vials and late-May 2020 for the 2 gram vials.

Updated

Updated May 4, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide